WO2022154780A1 - Harvesting bovine embryonic inner cell mass cells - Google Patents
Harvesting bovine embryonic inner cell mass cells Download PDFInfo
- Publication number
- WO2022154780A1 WO2022154780A1 PCT/US2021/013159 US2021013159W WO2022154780A1 WO 2022154780 A1 WO2022154780 A1 WO 2022154780A1 US 2021013159 W US2021013159 W US 2021013159W WO 2022154780 A1 WO2022154780 A1 WO 2022154780A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- icm
- medium
- blastocyst
- cell
- cells
- Prior art date
Links
- 241000283690 Bos taurus Species 0.000 title claims abstract description 30
- 238000003306 harvesting Methods 0.000 title abstract description 10
- 210000002459 blastocyst Anatomy 0.000 claims abstract description 51
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 210000004027 cell Anatomy 0.000 claims description 77
- 239000002609 medium Substances 0.000 claims description 33
- 210000004340 zona pellucida Anatomy 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 19
- 238000012258 culturing Methods 0.000 claims description 16
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 15
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 11
- 230000004069 differentiation Effects 0.000 claims description 10
- 210000002950 fibroblast Anatomy 0.000 claims description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 9
- 239000012894 fetal calf serum Substances 0.000 claims description 8
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 8
- 238000005553 drilling Methods 0.000 claims description 7
- 239000012091 fetal bovine serum Substances 0.000 claims description 7
- 238000010899 nucleation Methods 0.000 claims description 7
- 238000000608 laser ablation Methods 0.000 claims description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 5
- 210000000663 muscle cell Anatomy 0.000 claims description 5
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 4
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 4
- 210000001789 adipocyte Anatomy 0.000 claims description 4
- 210000003321 cartilage cell Anatomy 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 229940054269 sodium pyruvate Drugs 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 3
- 210000001608 connective tissue cell Anatomy 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 235000020776 essential amino acid Nutrition 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000007758 minimum essential medium Substances 0.000 claims description 3
- 238000011536 re-plating Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 108010059712 Pronase Proteins 0.000 claims description 2
- 229940012957 plasmin Drugs 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 12
- 210000001161 mammalian embryo Anatomy 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001720 carbohydrates Chemical group 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 210000001900 endoderm Anatomy 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RDEIXVOBVLKYNT-HDZPSJEVSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-[(1r)-1-aminoethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2 Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)[C@@H](C)N)N)[C@@H](N)C[C@H]1N.O1[C@H]([C@@H](C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-HDZPSJEVSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000004140 Oncostatin M Human genes 0.000 description 1
- 108090000630 Oncostatin M Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 101001023030 Toxoplasma gondii Myosin-D Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- ISQINHMJILFLAQ-UHFFFAOYSA-N argon hydrofluoride Chemical compound F.[Ar] ISQINHMJILFLAQ-UHFFFAOYSA-N 0.000 description 1
- 210000004952 blastocoel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002406 microsurgery Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 210000000472 morula Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002993 trophoblast Anatomy 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L13/00—Meat products; Meat meal; Preparation or treatment thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
Definitions
- the disclosure is directed to methods, systems and compositions for isolating inner cell mass (ICM) from bovine blastocysts. More specifically, the disclosure is directed to methods for harvesting ICM from bovine blastocysts, the systems used to implement the methods and the compositions used to culture the harvested ICM for the formation of tissue culture.
- ICM inner cell mass
- Embryonic stem (ES) cells are special kind of cells that can both duplicate themselves (in other words, divide and proliferate indefinitely in culture) and produce differentiated functionally specialized cell types. These stem cells are capable of becoming almost all of the specialized cells of the body and thus, may have the potential to generate cells for a broad array of tissues such as, for example, muscle, cartilage and the like.
- a method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst comprising the steps of: obtaining a plurality of blastocysts, each blastocyst having: a zona pellucida; a trophectoderm, and an inner cell mass; perforating each blastocyst; isolating the ICM from each blastocyst through the perforations; seeding the ICM on a predetermined substrate; and culturing the ICM to establish a bovine ICM tissue culture.
- FIG. 1. is an embodiment of the primary method for isolating inner cell mass (ICM) from bovine blastocysts;
- FIG. 2 illustrating a schematic representation of a bovine blastocyst.
- ICM inner cell mass
- bovine blastocysts cultured to emulate tissue and/or organs for (nonvegan) food consumption.
- the egg is surrounded by the zona pellucida. After fertilization, the egg cleaves to form a cluster of cells called the morula. After the 32 cell stage (in cattle), an internal cavity (blastocoel) forms and the cluster is called a blastocyst.
- One pole of the blastocyst has a thicker accumulation of cells, known as the inner cell mass (ICM). The entire embryo proper is derived from the inner cell mass.
- Embryonic stem (ES) cells are found in the ICM of the bovine blastocyst, an early stage of the developing embryo lasting from about the 9 th to about 12 th day after fertilization.
- the blastocyst is the stage of embryonic development prior to implantation that contains two types of cells; namely: the Trophectoderm - the outer layer which gives extra embryonic membranes; and the Inner cell mass (ICM): which forms the embryo proper.
- ES cells (ESC) - like cells referring to a pluripotent cell characterized by the properties of ESC such as, for example, proliferation without transformation, infinite replication, self-renewal and differentiation into all three germ layers; endoderm, mesoderm, and ectoderm), extracted from the ICM during the blastocyst stage, can be cultured in the laboratory and under the right conditions proliferate indefinitely. ES cells growing in this undifferentiated state retain the potential to differentiate into cells of all three embryonic tissue layers. Ultimately, the cells of the inner cell mass give rise to all the embryonic tissues. It is at this stage of embryogenesis, near the end of first week of development, that ES cells can be derived from the ICM of the blastocyst.
- a method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst comprising the steps of: obtaining a plurality of blastocysts, each blastocyst having: a zona pellucida; a trophectoderm, and an inner cell mass; perforating each blastocyst; isolating the ICM from each blastocyst through the perforations; seeding the ICM on a predetermined substrate; and culturing the ICM to establish a bovine ICM tissue culture.
- the step of perforating the each blastocyst further comprises forming holes in at least one of: the zona pellucida (ZP) (see e.g., FIG. 2), and the trophectoderm (interchangeable with trophoblast).
- ZP zona pellucida
- the “zona pellucida” refers to the embryo shell and is intended to include the complex extracellular glycoprotein matrix surrounding the blastocyst as described above. It is also intended to include the deglycosylated or deglycated proteins that are included in the matrix; "deglycosylated protein” means the protein backbone of a glycoprotein molecule lacking some or all of its carbohydrate moieties.
- deglycated protein may also be used to define the protein backbone of a glycoprotein molecule lacking some or all of its carbohydrate moieties.
- Zona pellucida is also intended to include polypeptides having essentially the same amino acid sequence as the naturally occurring and recombinant Zona pellucida protein(s) and any analogs thereof.
- analogs is intended to include proteins or polypeptides which differ from natural Zona pellucida protein by addition, deletion or substitution of one or more amino acids, providing that polypeptide demonstrates substantially the antigenic, biologic and growth stimulant activity of natural Zona pellucida.
- tophectoderm refers, in the context of the disclosure to the outer layer of the blastocyst after differentiation of the ectoderm, mesoderm, and endoderm, when the outer layer is continuous with the ectoderm of the embryo
- the step of perforating the ZR and TE, in the methods for harvesting ICM from a plurality of blastocysts described herein, can be done using at least one of: electroporation, partial cell digestion, drilling, laser ablation, and slitting.
- electroporation meaning the temporary creation of holes or aqueous pores in the surface of a cell membrane can be done by an applying electrical potential and through which therapeutic agents may pass into and out of the cell depending on the existing chemical potential between the external and internal cell environment.
- Electroporation can be used also for thinning the ZP.
- ZP drilling is done using, for example, a microneedle filled with acidic Tyrode’s solution are positioned in an example, by holding the needle tip very close to the ZP at the embryo’ s pole, or diametrically opposed to the embryo’ s pole and locally contacting the zona with the solution.
- laser assisted cellular microsurgery can be used to create a hole in both the ZP and TE layers.
- argon fluoride excimer laser in the deep ultraviolet (UV) region of the spectrum at about 193 nm wavelength, guided through a glass pipette filled with a positive air pressure, where the hole diameter is controlled by the pipette tip diameter (for example, between micropipette having a tip diameter between about 25 pm and about 45 pm). It is noted that some or all of the methods disclosed for perforating the ZP and TE, can be used for thinning the ZP as well.
- At least one of: partial cell digestion, drilling, laser ablation, and slitting, is performed at each blastocyst’s pole (in other words, the location in the blastocyst exhibiting thicker accumulation of cells), or contralateral to the blastocyst’s pole
- the step of culturing (referring to the growth of cells in vitro in an artificial medium for commercial purpose), of the ICM to establish a bovine ICM tissue culture, in the methods, systems and compositions for harvesting ICM from a plurality of blastocysts described herein, can comprise culturing the cells of the ICM in the presence of (or in plating over) an embryonic stem cell medium and a feeder layer medium.
- the term “feeder layer” refers to a cell or cells used in co-culture to maintain stem cells as pluripotent.
- feeder layers can include, for example, at least one of: mouse (murine) embryonic fibroblasts (MEFs), and bovine embryonic fibroblasts (BEF) that have been treated to prevent them from dividing in culture.
- the feeder layer can comprise for example a combination of the MEF and BEF at a ratio of between about 9:11 to about 11:9 MEF:BEF. In an embodiment, the ratio between MEF and BEF is 1:1.
- the embryonic stem cell medium can be, for example, at least one of: a composition comprising: Dulbecco's modified Eagle's medium (DMEM) without Sodium pyruvate having glucose content of between about 70% and about 90%; between about 10% and about 30% Fetal bovine serum (FBS); 0 -mercaptoethanol (0.1 mM); about 1% of non-essential amino acids; E-Glutamine 2 mM; and basic fibroblast growth factor (BFGF), a composition comprising: Minimum Essential Medium Alpha (MEM-oc) with 10% inactivated fetal calf serum, and a composition comprising: DMEM; 15% Fetal bovine serum; Penicillin/ Streptomyocin; Glutamine; Non-essential amino acids; nucleosides; 0-mercaptoethanol; Sodium pyruvate; and leukaemia inhibitory factor (LIF).
- DMEM Dulbecco's modified Eagle's medium
- FBS Fetal bovine serum
- Other embryo culture and maturation media routinely used for the collection and maintenance of embryos can be, for example, Ham's F-10+10% fetal calf serum (FCS), Tissue Culture Medium-199 (TCM-199)+10% fetal calf serum, Tyrodes-Albumin-Eactate-Pyruvate (TAEP), Dulbecco's Phosphate Buffered Saline (PBS), Eagle's and Whitten's media.
- FCS Ham's F-10+10% fetal calf serum
- TCM-199 Tissue Culture Medium-199
- TCM-199 Tyrodes-Albumin-Eactate-Pyruvate
- PBS Dulbecco's Phosphate Buffered Saline
- Eagle's and Whitten's media for example TCM-199, and 1 to 20% serum supplement including fetal calf serum, newborn serum, estrual cow serum, lamb serum or steer serum.
- An example of maintenance medium can be TCM-199 with Earl salts, 10% fetal calf serum, 0.2 mM pyruvate and 50 pg/ml gentamicin sulphate. Any of the above may also involve co-culture with a variety of cell types forming a feeder layer such as, at least one of: granulosa cells, oviduct cells, BRL cells, and uterine cells.
- the ICM harvested ESC-like cells may be subsequently cultured in differentiation medium, operable to cause the culture to differentiate to at least one of: a muscle cell, a cartilage cell, a fat cell, and a connective tissue cell.
- differentiation and its derivatives, as used with respect to cells in a differentiating cell system, refers to the process by which cells differentiate from one cell type (e.g., a multipotent, totipotent or pluripotent differentiable cell) to another cell type such as a target-differentiated cell (e.g., a muscle cell, a cartilage cell, a fat cell, a neuron cell, and the like).
- Myocytes differentiation can be done by, for example, by employing pharmacologic inhibitors and agonists (e.g., for upregulation of Mesogeninl) as well as isolated cytokines or other protein-based signals, for example, to cause overexpression of myogenic transcription factor MyoD.
- pharmacologic inhibitors and agonists e.g., for upregulation of Mesogeninl
- isolated cytokines or other protein-based signals for example, to cause overexpression of myogenic transcription factor MyoD.
- a process whereby the unspecialized ICM derived ESC-like cells acquires the features of a specialized cell such as a muscle cell. Differentiation is controlled by the interaction of the cells’ genes with the physical and chemical conditions outside the cell, for example, through signaling pathways involving proteins embedded in the cell surface.
- the step of seeding the ICM is preceded by forming a suspended mixture of the ICM.
- the suspended cells can be, for example, cells’ dispersion, solution, emulsion, suspension, hydrogel or liquid compositions.
- culturing the isolated ICM ESC-like cell mass further comprises mechanically dissociating the ICM and re-plating the ICM on the feeder layer disclosed.
- compositions used in the methods disclosed can further comprise other additives that affect colonization, proliferation, adherence, inhibit apoptosis or other manipulation of the cells, retain native growth of the cells, and/or organ and/or tissue and other similar functions, for example: cells manipulation triggering compounds, (for example, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), bone morphogenic protein (BMP), insulin-like growth factor (IGF), glucoseaminoglycan (GAG), Transforming growth factor (TGF) or signaling compound composition comprising the foregoing), as well as therapeutically effective compounds, antimicrobial compounds, immunosuppressing compounds and the like.
- cells manipulation triggering compounds for example, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), bone morphogenic protein (BMP), insulin-like growth factor (IGF), glucoseaminoglycan (GAG), Transforming growth factor (TGF) or signaling compound composition comprising the foregoing
- EGF epidermal growth factor
- a method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst comprising the steps of: obtaining a plurality of blastocysts, each blastocyst having: a zona pellucida (ZP); a trophectoderm (TE), and an inner cell mass (ICM); perforating each blastocyst; isolating the ICM from each blastocyst through the perforations; seeding the ICM on a predetermined substrate; and culturing the ICM to establish a bovine ICM tissue culture, wherein (i) the step of perforating comprising forming holes in at least one of the ZP, and the TE, (ii) is performed by at least one of: electroporation, drilling, laser ablation, and slitting, wherein (iii) the blastocyst is preceded by a step of
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The disclosure relates to methods, systems and compositions for isolating inner cell mass (ICM) from bovine blastocysts. More specifically, the disclosure is directed to methods for harvesting ICM from bovine blastocysts, the systems used to implement the methods and the compositions used to culture the harvested ICM for the formation of tissue culture.
Description
HARVESTING BOVINE EMBRYONIC INNER CELL MASS CELLS
BACKGROUND
[0001] The disclosure is directed to methods, systems and compositions for isolating inner cell mass (ICM) from bovine blastocysts. More specifically, the disclosure is directed to methods for harvesting ICM from bovine blastocysts, the systems used to implement the methods and the compositions used to culture the harvested ICM for the formation of tissue culture.
[0002] In an effort to reduce the impact of animal agriculture and to improve people's nutrition, as well as for various other incentives, there is a need for alternatives to animal meat for development of novel protein sources containing viable cells culture(s) that correspond to the three-dimensional (3D) tissue, for instance, muscle tissue.
[0003] Embryonic stem (ES) cells are special kind of cells that can both duplicate themselves (in other words, divide and proliferate indefinitely in culture) and produce differentiated functionally specialized cell types. These stem cells are capable of becoming almost all of the specialized cells of the body and thus, may have the potential to generate cells for a broad array of tissues such as, for example, muscle, cartilage and the like.
[0004] Therefore, the need exists for methods, systems and compositions for harvesting the ES for the commercial production of tissue culture to form tissues that can be used as substitute for meat.
SUMMARY
[0005] Disclosed, in various embodiments, are methods, systems and compositions for harvesting ICM from bovine blastocysts.
[0006] In an embodiment provided herein is a method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst, comprising the steps of: obtaining a plurality of blastocysts, each blastocyst having: a zona pellucida; a trophectoderm, and an inner cell mass; perforating each blastocyst; isolating the ICM from each blastocyst through the perforations; seeding the ICM on a predetermined substrate; and culturing the ICM to establish a bovine ICM tissue culture.
BRIEF DESCRIPTION OF THE FIGURES
[0007] For a better understanding of the methods for isolating inner cell mass (ICM) from bovine blastocysts, with regard to the embodiments thereof, reference is made to the accompanying examples and figures, in which:
[0008] FIG. 1. is an embodiment of the primary method for isolating inner cell mass (ICM) from bovine blastocysts; and
[0009] FIG. 2, illustrating a schematic representation of a bovine blastocyst..
DETAILED DESCRIPTION
[00010] Provided herein are embodiments of methods, systems and compositions for isolating inner cell mass (ICM) from bovine blastocysts, cultured to emulate tissue and/or organs for (nonvegan) food consumption. At the early stages of development, the egg is surrounded by the zona pellucida. After fertilization, the egg cleaves to form a cluster of cells called the morula. After the 32 cell stage (in cattle), an internal cavity (blastocoel) forms and the cluster is called a blastocyst. One pole of the blastocyst has a thicker accumulation of cells, known as the inner cell mass (ICM). The entire embryo proper is derived from the inner cell mass.
[00011] Embryonic stem (ES) cells are found in the ICM of the bovine blastocyst, an early stage of the developing embryo lasting from about the 9th to about 12th day after fertilization. The blastocyst is the stage of embryonic development prior to implantation that contains two types of cells; namely: the Trophectoderm - the outer layer which gives extra embryonic membranes; and the Inner cell mass (ICM): which forms the embryo proper. ES cells (ESC) - like cells (referring to a pluripotent cell characterized by the properties of ESC such as, for example, proliferation without transformation, infinite replication, self-renewal and differentiation into all three germ layers; endoderm, mesoderm, and ectoderm), extracted from the ICM during the blastocyst stage, can be cultured in the laboratory and under the right conditions proliferate indefinitely. ES cells growing in this undifferentiated state retain the potential to differentiate into cells of all three embryonic tissue layers. Ultimately, the cells of the inner cell mass give rise to all the embryonic tissues. It is at this stage of embryogenesis, near the end of first week of development, that ES cells can be derived from the ICM of the blastocyst.
[00012] Accordingly and in an embodiment, provided herein is a method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst, comprising the steps of: obtaining a plurality of blastocysts, each blastocyst having: a zona pellucida; a trophectoderm, and an inner cell mass; perforating each blastocyst; isolating the ICM from each blastocyst through the perforations;
seeding the ICM on a predetermined substrate; and culturing the ICM to establish a bovine ICM tissue culture.
[00013] As illustrated in the flowchart of FIG. 1, the step of perforating the each blastocyst further comprises forming holes in at least one of: the zona pellucida (ZP) (see e.g., FIG. 2), and the trophectoderm (interchangeable with trophoblast). In the context of the disclosure, the “zona pellucida” refers to the embryo shell and is intended to include the complex extracellular glycoprotein matrix surrounding the blastocyst as described above. It is also intended to include the deglycosylated or deglycated proteins that are included in the matrix; "deglycosylated protein" means the protein backbone of a glycoprotein molecule lacking some or all of its carbohydrate moieties. The term "deglycated protein" may also be used to define the protein backbone of a glycoprotein molecule lacking some or all of its carbohydrate moieties. "Zona pellucida" is also intended to include polypeptides having essentially the same amino acid sequence as the naturally occurring and recombinant Zona pellucida protein(s) and any analogs thereof. The term "analogs" is intended to include proteins or polypeptides which differ from natural Zona pellucida protein by addition, deletion or substitution of one or more amino acids, providing that polypeptide demonstrates substantially the antigenic, biologic and growth stimulant activity of natural Zona pellucida. Additionally, “tophectoderm” (TE) refers, in the context of the disclosure to the outer layer of the blastocyst after differentiation of the ectoderm, mesoderm, and endoderm, when the outer layer is continuous with the ectoderm of the embryo
[00014] The step of perforating the ZR and TE, in the methods for harvesting ICM from a plurality of blastocysts described herein, can be done using at least one of: electroporation, partial cell digestion, drilling, laser ablation, and slitting. For example, electroporation meaning the temporary creation of holes or aqueous pores in the surface of a cell membrane can be done by an applying electrical potential and through which therapeutic agents may pass into and out of the cell depending on the existing chemical potential between the external and internal cell environment. In an example, Electroporation can be used also for thinning the ZP. Likewise, ZP drilling is done using, for example, a microneedle filled with acidic Tyrode’s solution are positioned in an example, by holding the needle tip very close to the ZP at the embryo’ s pole, or diametrically opposed to the embryo’ s pole and locally contacting the zona with the solution. Similarly, laser assisted cellular microsurgery can be used to create a hole in both the ZP and TE layers. For example, by using an argon fluoride excimer laser, in the deep ultraviolet (UV) region of the spectrum at about 193 nm wavelength, guided through a glass
pipette filled with a positive air pressure, where the hole diameter is controlled by the pipette tip diameter (for example, between micropipette having a tip diameter between about 25 pm and about 45 pm). It is noted that some or all of the methods disclosed for perforating the ZP and TE, can be used for thinning the ZP as well. In an embodiment, at least one of: partial cell digestion, drilling, laser ablation, and slitting, is performed at each blastocyst’s pole (in other words, the location in the blastocyst exhibiting thicker accumulation of cells), or contralateral to the blastocyst’s pole
[00015] In an embodiment, the step of culturing (referring to the growth of cells in vitro in an artificial medium for commercial purpose), of the ICM to establish a bovine ICM tissue culture, in the methods, systems and compositions for harvesting ICM from a plurality of blastocysts described herein, can comprise culturing the cells of the ICM in the presence of (or in plating over) an embryonic stem cell medium and a feeder layer medium. In the context of the disclosure, the term “feeder layer” refers to a cell or cells used in co-culture to maintain stem cells as pluripotent. For bovine embryonic stem cell culture, feeder layers can include, for example, at least one of: mouse (murine) embryonic fibroblasts (MEFs), and bovine embryonic fibroblasts (BEF) that have been treated to prevent them from dividing in culture. The feeder layer can comprise for example a combination of the MEF and BEF at a ratio of between about 9:11 to about 11:9 MEF:BEF. In an embodiment, the ratio between MEF and BEF is 1:1. Furthermore, the embryonic stem cell medium, can be, for example, at least one of: a composition comprising: Dulbecco's modified Eagle's medium (DMEM) without Sodium pyruvate having glucose content of between about 70% and about 90%; between about 10% and about 30% Fetal bovine serum (FBS); 0 -mercaptoethanol (0.1 mM); about 1% of non-essential amino acids; E-Glutamine 2 mM; and basic fibroblast growth factor (BFGF), a composition comprising: Minimum Essential Medium Alpha (MEM-oc) with 10% inactivated fetal calf serum, and a composition comprising: DMEM; 15% Fetal bovine serum; Penicillin/ Streptomyocin; Glutamine; Non-essential amino acids; nucleosides; 0-mercaptoethanol; Sodium pyruvate; and leukaemia inhibitory factor (LIF).
[00016] Other embryo culture and maturation media routinely used for the collection and maintenance of embryos, used in connection with the methods disclosed, can be, for example, Ham's F-10+10% fetal calf serum (FCS), Tissue Culture Medium-199 (TCM-199)+10% fetal calf serum, Tyrodes-Albumin-Eactate-Pyruvate (TAEP), Dulbecco's Phosphate Buffered Saline (PBS), Eagle's and Whitten's media. For example TCM-199, and 1 to 20% serum supplement including fetal calf serum, newborn serum, estrual cow serum, lamb serum or steer serum. An example of maintenance medium can be TCM-199 with Earl salts, 10% fetal calf serum, 0.2 mM pyruvate and 50 pg/ml
gentamicin sulphate. Any of the above may also involve co-culture with a variety of cell types forming a feeder layer such as, at least one of: granulosa cells, oviduct cells, BRL cells, and uterine cells.
[00017] The ICM harvested ESC-like cells may be subsequently cultured in differentiation medium, operable to cause the culture to differentiate to at least one of: a muscle cell, a cartilage cell, a fat cell, and a connective tissue cell. The term “differentiate” and its derivatives, as used with respect to cells in a differentiating cell system, refers to the process by which cells differentiate from one cell type (e.g., a multipotent, totipotent or pluripotent differentiable cell) to another cell type such as a target-differentiated cell (e.g., a muscle cell, a cartilage cell, a fat cell, a neuron cell, and the like). For example, differentiation into hematopoietic and endothelial cell lineages in the presence of (exposed to) a composition comprising: bFGF; stem cell factor; and oncostatin M. Myocytes differentiation can be done by, for example, by employing pharmacologic inhibitors and agonists (e.g., for upregulation of Mesogeninl) as well as isolated cytokines or other protein-based signals, for example, to cause overexpression of myogenic transcription factor MyoD. In other words, a process whereby the unspecialized ICM derived ESC-like cells acquires the features of a specialized cell such as a muscle cell. Differentiation is controlled by the interaction of the cells’ genes with the physical and chemical conditions outside the cell, for example, through signaling pathways involving proteins embedded in the cell surface.
[00018] In the methods for harvesting ICM from a plurality of blastocysts described herein, the step of seeding the ICM is preceded by forming a suspended mixture of the ICM. The suspended cells can be, for example, cells’ dispersion, solution, emulsion, suspension, hydrogel or liquid compositions.
[00019] Furthermore, culturing the isolated ICM ESC-like cell mass further comprises mechanically dissociating the ICM and re-plating the ICM on the feeder layer disclosed.
[00020] Under certain circumstances, the compositions used in the methods disclosed, can further comprise other additives that affect colonization, proliferation, adherence, inhibit apoptosis or other manipulation of the cells, retain native growth of the cells, and/or organ and/or tissue and other similar functions, for example: cells manipulation triggering compounds, (for example, epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), bone morphogenic protein (BMP), insulin-like growth factor (IGF), glucoseaminoglycan (GAG), Transforming growth factor (TGF) or signaling compound composition comprising the foregoing), as well as therapeutically effective compounds, antimicrobial compounds, immunosuppressing compounds and the like.
[00021] The term "comprising" and its derivatives, as used herein, are intended to be open ended terms that specify the presence of the stated features, elements, components, groups, integers, and/or steps, but do not exclude the presence of other unstated features, elements, components, groups, integers and/or steps. The foregoing also applies to words having similar meanings such as the terms, "including", "having" and their derivatives.
[00022] All ranges disclosed herein are inclusive of the endpoints, and the endpoints are independently combinable with each other. “Combination” is inclusive of blends, mixtures, alloys, reaction products, and the like. The terms “a”, “an” and “the” herein do not denote a limitation of quantity, and are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The suffix “(s)” as used herein is intended to include both the singular and the plural of the term that it modifies, thereby including one or more of that term (e.g., the cell(s) includes one or more cell). Reference throughout the specification to “one embodiment”, “another embodiment”, “an embodiment”, and so forth, when present, means that a particular element (e.g., feature, structure, and/or characteristic) described in connection with the embodiment is included in at least one embodiment described herein, and may or may not be present in other embodiments. In addition, it is to be understood that the described elements may be combined in any suitable manner in the various embodiments.
[00023] All ranges disclosed herein are inclusive of the endpoints, and the endpoints are independently combinable with each other. Furthermore, the term "about" means that amounts, sizes, formulations, parameters, and other quantities and characteristics are not and need not be exact, but may be approximate and/or larger or smaller, as desired, reflecting tolerances, conversion factors, rounding off, measurement error and the like, and other factors known to those of skill in the art. In general, an amount, size, formulation, parameter or other quantity or characteristic is "about" or "approximate" whether or not expressly stated to be such. For example, “about” as used herein mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms of degree should be construed as including a deviation of at least ±5% or at least ±10% of the modified term if this deviation would not negate the meaning of the word it modifies.
[00024] Accordingly and in an exemplary implementation, provided herein is a method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst, comprising the steps of: obtaining a plurality of blastocysts, each blastocyst having: a zona pellucida (ZP); a trophectoderm (TE), and an inner cell mass (ICM); perforating each blastocyst; isolating the ICM
from each blastocyst through the perforations; seeding the ICM on a predetermined substrate; and culturing the ICM to establish a bovine ICM tissue culture, wherein (i) the step of perforating comprising forming holes in at least one of the ZP, and the TE, (ii) is performed by at least one of: electroporation, drilling, laser ablation, and slitting, wherein (iii) the blastocyst is preceded by a step of thinning the ZP, wherein (iv) the step of culturing comprises culturing the cells of the ICM in the presence of an embryonic stem cell medium and a feeder layer medium, wherein (v) the embryonic stem cell medium is a composition comprising: Dulbecco's modified Eagle's medium without Sodium pyruvate having glucose content of between about 70% and about 90%; between about 10% and about 30% Fetal bovine serum (FBS); □/?-mercaptoethanol (0.1 mM); about 1% of non-essential amino acids; L-Glutamine 2 mM; and basic fibroblast growth factor (BFGF), wherein (vi) the feeder layer medium is at least one of a murine embryonic fibroblast medium, and a bovine embryonic fibroblast medium, with (vii) a predetermined ratio of murine embryonic fibroblast medium to bovine embryonic fibroblast medium, (viii) the ratio is between about 9:11 and about 11:9, wherein (ix) the step of seeding the ICM is preceded by forming a suspended mixture of the ICM, wherein (x) the suspended system is at least one of: a gel, an emulsion, and a suspension, (xi) further comprising mechanically dissociating the ICM and re-plating the ICM on the feeder layer, wherein (xii) at least one of: partial cell digestion, drilling, laser ablation, and slitting, is performed at each blastocyst’s pole, or contralateral to the blastocyst’s pole, wherein (xiii) the step of thinning the ZP comprises partially digesting the ZP, comprising (xiv) contacting the ZP with a composition comprising at least one of: urokinase-type plasminogen activator (uPA) and plasmin, and pronase, wherein (xv) the embryonic stem cell medium is a composition comprising: Minimum Essential Medium Alpha (MEM-oc) with 10% inactivated fetal calf serum, wherein (xvi) the step of culturing the cells of the ICM in the presence of an embryonic stem cell medium and a feeder layer medium, is followed by a step of culturing the cells of the ICM in the presence of a differentiation medium, and wherein (xvii) the differentiation medium is operable to cause the culture to differentiate to at least one of: a muscle cell, a cartilage cell, a fat cell, and a connective tissue cell.
[00025] Although the foregoing disclosure for harvesting ICM from bovine blastocysts has been described in terms of some embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Moreover, the described embodiments have been presented by way of example only, and are not intended to limit the scope of the inventions. Indeed, the novel methods, systems and compositions described herein may be embodied in a variety of other
forms without departing from the spirit thereof. Accordingly, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein.
Claims
1. A method for establishing a tissue culture from the inner cell mass (ICM) of a bovine blastocyst, comprising the steps of: a. obtaining a plurality of blastocysts, each blastocyst having: i. a zona pellucida (ZP); ii. a trophectoderm (TE), and iii. an inner cell mass (ICM); b. perforating each blastocyst; c. isolating the ICM from each blastocyst through the perforations; d. seeding the ICM on a predetermined substrate; and e. culturing the ICM to establish a bovine ICM tissue culture.
2. The method of claim 1, wherein the step of perforating comprising forming holes in at least one of the ZP, and the TE.
3. The method of claim 2, wherein the step of perforating is performed by at least one of: electroporation, drilling, laser ablation, and slitting.
4. The method of claim 3, wherein the step of perforating the blastocyst is preceded by a step of thinning the ZP.
5. The method of claim 1, wherein the step of culturing comprises culturing the cells of the ICM in the presence of an embryonic stem cell medium and a feeder layer medium.
6. The method of claim 5, wherein the embryonic stem cell medium is a composition comprising: a. Dulbecco's modified Eagle's medium without Sodium pyruvate having glucose content of between about 70% and about 90%; b. between about 10% and about 30% Fetal bovine serum (FBS); c. ^mercaptoethanol (0.1 mM); d. about 1% of non-essential amino acids; e. L- Glutamine 2 mM; and f. basic fibroblast growth factor (BFGF)
7. The method of claim 5, wherein the feeder layer medium is at least one of a murine embryonic fibroblast medium, and a bovine embryonic fibroblast medium.
9
8. The method of claim 7, wherein the feeder layer medium is a composition comprising a predetermined ratio of murine embryonic fibroblast medium to bovine embryonic fibroblast medium.
9. The method of claim 8, wherein the ratio is between about 9:11 and about 11:9
10. The method of claim 1, wherein the step of seeding the ICM is preceded by forming a suspended mixture of the ICM.
11. The method of claim 10, wherein the suspended system is at least one of: a gel, an emulsion, and a suspension.
12. The method of claim 7, wherein the step of culturing further comprises mechanically dissociating the ICM and re-plating the ICM on the feeder layer.
13. The method of claim 3, wherein at least one of: partial cell digestion, drilling, laser ablation, and slitting, is performed at each blastocyst’s pole, or contralateral to the blastocyst’s pole.
14. The method of claim 4, wherein the step of thinning the ZP comprises partially digesting the ZP.
15. The method of claim 14, wherein the step of partially digestin the ZP comprises contacting the ZP with a composition comprising at least one of: urokinase-type plasminogen activator (uPA) and plasmin, and pronase.
16. The method of claim 5, wherein the embryonic stem cell medium is a composition comprising: Minimum Essential Medium Alpha (MEM-oc) with 10% inactivated fetal calf serum.
17. The method of claim 5, wherein the step of culturing the cells of the ICM in the presence of an embryonic stem cell medium and a feeder layer medium, is followed by a step of culturing the cells of the ICM in the presence of a differentiation medium.
18. The method of claim 17, wherein the differentiation medium is operable to cause the culture to differentiate to at least one of: a muscle cell, a cartilage cell, a fat cell, and a connective tissue cell.
Blank page received at the International Bureau
11
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/013159 WO2022154780A1 (en) | 2021-01-13 | 2021-01-13 | Harvesting bovine embryonic inner cell mass cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2021/013159 WO2022154780A1 (en) | 2021-01-13 | 2021-01-13 | Harvesting bovine embryonic inner cell mass cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022154780A1 true WO2022154780A1 (en) | 2022-07-21 |
Family
ID=82448615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/013159 WO2022154780A1 (en) | 2021-01-13 | 2021-01-13 | Harvesting bovine embryonic inner cell mass cells |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022154780A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100138947A1 (en) * | 2005-04-29 | 2010-06-03 | Ivan Vassiliev | Method for Producing Stem Cells or Stel Cell-Like Cells from Mammalian Embryos |
WO2019140260A1 (en) * | 2018-01-12 | 2019-07-18 | The Regents Of The University Of California | Efficient derivation of stable pluripotent bovine embryonic stem cells |
-
2021
- 2021-01-13 WO PCT/US2021/013159 patent/WO2022154780A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100138947A1 (en) * | 2005-04-29 | 2010-06-03 | Ivan Vassiliev | Method for Producing Stem Cells or Stel Cell-Like Cells from Mammalian Embryos |
WO2019140260A1 (en) * | 2018-01-12 | 2019-07-18 | The Regents Of The University Of California | Efficient derivation of stable pluripotent bovine embryonic stem cells |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10329532B2 (en) | Method to direct differentiation of pluripotent stem cells into functional heart muscle | |
JP4889902B2 (en) | Method for producing human neural progenitor cells from human embryonic stem (hES) cells, method for producing neurons using the method, method for producing oligodendrocytes or astrocytes | |
JP5227318B2 (en) | Cell growth medium | |
Shah et al. | Hand-made cloned buffalo (Bubalus bubalis) embryos: comparison of different media and culture systems | |
Gandolfi et al. | Why is it so difficult to derive pluripotent stem cells in domestic ungulates? | |
SG177946A1 (en) | Media for culturing stem cells | |
US20090075374A1 (en) | Methods of generating epithelial lineage cells from embryoid bodies and pluripotent cells | |
Luijkx et al. | From mice to men: generation of human blastocyst-like structures in vitro | |
US11098282B1 (en) | Serum-free culture medium for in vitro maturation of bovine oocytes and a method for culture of oocytes | |
JP2023550549A (en) | Media and methods for establishing and maintaining early embryo-like cells | |
WO2022154780A1 (en) | Harvesting bovine embryonic inner cell mass cells | |
CN116751738A (en) | Signal nest cell and embryo-like preparation method | |
EP3812454A1 (en) | Medium composition for culturing porcine pluripotent stem cells | |
KR102469369B1 (en) | Medium composition for in vitro culture of mammalian fertilized eggs containing interleukin 7 | |
US20240174985A1 (en) | Method for producing ovarian somatic cell-like cells, and method for inducing differentiation of primate pluripotent stem cells into ovarian somatic cell-like cells | |
Tian et al. | Factors derived from mouse embryonic stem cells promote self-renewal of goat embryonic stem-like cells | |
US20230313127A1 (en) | Compositions and methods for embryonic stem cell expansion | |
CN113583944A (en) | Application of activated Wnt/beta-catenin signal path in improving production efficiency of buffalo in vitro embryos | |
WO2022155377A1 (en) | Bovine umbilical cord stem cells as feeder layer for embryonic stem cell propagation | |
Bhat et al. | The role of embryonic stem cells, transcription and growth factors in mammals: A review | |
WO2022163670A1 (en) | Culture technique for differentiating ovarian tissue from pluripotent stem cells | |
WO2023157852A1 (en) | Method for inducing differentiation from pluripotent stem cell to epidermal keratinocyte | |
KR20060114381A (en) | Medium for preparing feeder cells for embryonic stem cells and feeder cells | |
US20230119089A1 (en) | Method for differentiating pluripotent stem cells into underlying connective tissue fibroblasts of an epithelium | |
Sun et al. | Effects of group culture on the development of discarded human embryos and the construction of human embryonic stem cell lines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21920003 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21920003 Country of ref document: EP Kind code of ref document: A1 |